|Neisseria gonorrhoeae cultured on two different media types and presented in stereoscopic 3d.|
Gonococcus Neisser 1879
Neisseria gonorrhoeae, also known as gonococci (plural), or gonococcus (singular), is a species of Gram-negative coffee bean-shaped diplococci bacteria responsible for the sexually transmitted infection gonorrhea.
N. gonorrhoea was first described by Albert Neisser in 1879.
Neisseria are fastidious Gram-negative cocci that require nutrient supplementation to grow in laboratory cultures. To be specific, they grow on chocolate agar with carbon dioxide. These cocci are facultatively intracellular and typically appear in pairs (diplococci), in the shape of coffee beans. Of the eleven species of Neisseria that colonize humans, only two are pathogens. N. gonorrhoeae is the causative agent of gonorrhea (also called "The Clap," which is derived from the French word "clapier," meaning "brothel") and is transmitted via sexual contact.
Neisseria is usually isolated on Thayer-Martin agar (or VPN agar)—an agar plate containing antibiotics (vancomycin, colistin, nystatin, and trimethoprim) and nutrients that facilitate the growth of Neisseria species while inhibiting the growth of contaminating bacteria and fungi. Further testing to differentiate the species includes testing for oxidase (all clinically relevant Neisseria show a positive reaction) and the carbohydrates maltose, sucrose, and glucose test in which N. gonorrhoeae will oxidize (that is, utilize) only the glucose.
N. gonorrhoeae are motile (twitching motility) and possess type IV pili to adhere to surfaces. The type IV pili operate mechanistically similar to a grappling hook. Pili extend and attach to a substrate that signals the pilus to retract, dragging the cell forward. N. gonorrhoeae are able to pull 100,000 times their own weight, and it has been claimed that the pili used to do so are the strongest biological motor known to date, exerting one nanonewton.
N. gonorrhoeae has surface proteins called Opa proteins, which bind to receptors on immune cells. In so doing, N. gonorrhoeae is able to prevent an immune response. The host is also unable to develop an immunological memory against N. gonorrhoeae – which means that future reinfection is possible. N. gonorrhoeae can also evade the immune system through a process called antigenic variation, in which the N. gonorrhoeae bacterium is able to alter the antigenic determinants (sites where antibodies bind) such as the Opa proteins and Type IV pili that adorn its surface. The many permutations of surface proteins make it more difficult for immune cells to recognize N. gonorrhoeae and mount a defense.
N. gonorrhoeae is naturally competent for DNA transformation as well as being capable of conjugation. Both of these concepts allow for the DNA of N. gonorrhoeae the ability to undergo conformational changes. Especially dangerous to the health industry is the ability to conjugate, since this can lead to antibiotic resistance.
In 2011, researchers at Northwestern University found evidence of a human DNA fragment in a Neisseria gonorrhoeae genome, the first example of horizontal gene transfer from humans to a bacterial pathogen.
Symptoms of infection with N. gonorrhoeae differ, depending on the site of infection. Note also that 10% of infected males and 80% of infected females are asymptomatic.
Conjunctivitis is common in neonates (newborns), and silver nitrate or antibiotics are often applied to their eyes as a preventive measure against gonorrhoea. Neonatal gonorrheal conjunctivitis is contracted when the infant is exposed to N. gonorrhoeae in the birth canal and can lead to corneal scarring or perforation, resulting in blindness in the neonate.
Disseminated N. gonorrhoeae infections can occur, resulting in endocarditis, meningitis or gonococcal dermatitis-arthritis syndrome. Dermatitis-arthritis syndrome presents with arthralgia, tenosynovitis, and painless non-pruritic (non-itchy) dermatitis.
Infection of the genitals in females with N. gonorrhoeae can result in pelvic inflammatory disease if left untreated, which can result in infertility. Pelvic inflammatory disease results if N. gonorrhoeae travels into the pelvic peritoneum (via the cervix, endometrium and fallopian tubes). Infertility is caused by inflammation and scarring of the fallopian tube. Infertility is a risk to 10 to 20% of the females infected with N. gonorrhoeae.
Treatment and prevention
Antibiotic-resistant gonorrhea has been noted by epidemiologists; beginning in the 1940s, gonorrhea was treated with penicillin, but doses had to be continually increased in order to remain effective, and, by the ’70s, penicillin- and tetracycline-resistant gonorrhea emerged in the Pacific Basin. These resistant strains then spread to Hawaii, California, the rest of the United States, and Europe. Fluoroquinolones were the next line of defense, but soon resistance to this antibiotic emerged as well. Since 2007, standard treatment has been third-generation cephalosporins, such as ceftriaxone, which are considered to be our “last line of defense.”
Recently, a high-level ceftriaxone-resistant strain of gonorrhea, called H041, was discovered in Japan. Lab tests found it to be resistant to high concentrations of ceftriaxone, as well as most of the other antibiotics tested. Within N. gonorrhoeae, there are genes that confer resistance to every single antibiotic used to cure gonorrhea, but thus far they do not coexist within a single gonococcus. Because of N. gonorrhoeae’s high affinity for horizontal gene transfer, however, antibiotic-resistant gonorrhea is seen as an emerging public health threat.
Patients should also be tested for other sexually transmitted infections, especially Chlamydia infections, since co-infection is frequent (up to 50% of cases). Antibacterial coverage is often included for Chlamydia because of this.
Transmission can be reduced by the usage of latex barriers, such as condoms or dental dams, during intercourse, oral and anal sex, and by limiting sexual partners.
Due to the relative frequency of infection and the emerging development of antibiotic resistance in strains of N. gonorrhoeae, vaccines are thought to be an important goal in the prevention of infection. However, there has been a relatively low emphasis on research to such a vaccine in the medical literature and few human clinical trials for prospective vaccines. The ability to develop an effective vaccine has been limited by the lack of acquired immunity to infection to model a vaccine after and the current lack of commitment in effort and resources.
Survival of gonococci
The exudates from infected individuals contain many polymorphonuclear leukocytes (PMN) with ingested gonococci. These gonococci stimulate the PMN to release an internal oxidative burst involving reactive oxygen species in order to kill the gonococci. However, a significant fraction of the gonococci can resist killing and are able to reproduce within the PMN phagosomes.
Stohl and Seifert showed that the bacterial RecA protein, that mediates recombinational repair of DNA damage, plays an important role in gonococcal survival. The protection afforded by RecA protein may be linked to transformation, the process by which recipient gonococci take up DNA from neighboring gonococci and integrate this DNA into the recipient genome through recombination. Michod et al. have suggested that an important benefit of transformation in N. gonorrhoeae may be recombinational repair of oxidative DNA damages caused by oxidative attack by the hosts phagocytic cells.
- Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. ISBN 0-8385-8529-9.
- Genco, C; Wetzler, L (editors) (2010). Neisseria: Molecular Mechanisms of Pathogenesis. Caister Academic Press. ISBN 978-1-904455-51-6.
- "Mighty microbe pulls 100,000 times its bodyweight". New Scientist. 19 April 2008. Retrieved 2009-07-01.
- Stern, Anne; Brown, Nickel, Meyer (10 October 1986). "Opacity genes in Neisseria gonorrhoeae: Control of phase and antigenic variation". Cell 47 (1).
- Cahoon, Laty; Seifert (4 August 2011). "Focusing homologous recombination: pilin antigenic variation in the pathogenic Neisseria". Mol. Microbiol. 81 (5): 1136–1143.
- STI Awareness: Gonorrhea. Planned Parenthood Advocates of Arizona. 11 April 2011. Retrieved 31 August 2011.
- "Gonorrhea Acquires a Piece of Human DNA: First Evidence of Gene Transfer from Human Host to Bacterial Pathogen". ScienceDaily.com. 13 February 2011. Retrieved 15 February 2011.
- Anderson, Mark T.; H. Steven Seifert (15 Feb 2011). "Opportunity and Means: Horizontal Gene Transfer from the Human Host to a Bacterial Pathogen". MBio 2 (1): e00005–11. doi:10.1128/mBio.00005-11. PMC 3042738. PMID 21325040.
- "UK doctors advised gonorrhoea has turned drug resistant". BBC News. 10 October 2011.
- STI Awareness: Antibiotic-Resistant Gonorrhea. Planned Parenthood Advocates of Arizona. 6 March 2012. Retrieved 6 March 2012.
- Zhu W, Chen CJ, Thomas CE, Anderson JE, Jerse AE, Sparling PF (2011). "Vaccines for gonorrhea: can we rise to the challenge?". Front Microbiol 2: 124. doi:10.3389/fmicb.2011.00124. PMC 3109613. PMID 21687431.
- Simons MP, Nauseef WM, Apicella MA (2005). Interactions of Neisseria gonorrhoeae with adherent polymorphonuclear leukocytes. Infect Immun 73(4):1971-1977. PMID 1578453
- Stohl EA, Seifert HS (2006). Neisseria gonorrhoeae DNA recombination and repair enzymes protect against oxidative damage caused by hydrogen peroxide. J Bacteriol 188(21):7645-7651. PMID 16936020
- Michod RE, Bernstein H, Nedelcu AM (2008). Adaptive value of sex in microbial pathogens. Infect Genet Evol 8(3):267-285. Review. PMID 18295550 http://www.hummingbirds.arizona.edu/Faculty/Michod/Downloads/IGE%20review%20sex.pdf